top of page
Browse by category
Search


Vogenx announces positive results from second phase 2 study of mizagliflozin in post-bariatric hypoglycaemia
Vogenx has announced positive results from study VGX 001-012 evaluating mizagliflozin in patients diagnosed with post-bariatric...


Specific gut bacteria are involved in compulsive eating and obesity
An international team of researchers has identified specific bacteria in the gut that are associated with both mice and humans developing...


The role of patient outcomes in driving business success for bariatric clinics
Over the last few years, the demand for bariatric services has grown steadily - as more people have become aware of the risks that are...

Xeno Biosciences initiate phase 1b proof-of-concept study for obesity drug candidate XEN-101
Xeno Biosciences has initiated a Phase 1b clinical study designed to provide proof-of-concept weight loss results, along with safety and...


Specialist weight-loss services in England unable to keep up with spiralling demand
One in six integrated care boards (ICBs) in England have stopped accepting new patients for specialist weight management services as...

Journal Watch 26/06/2024
Welcome to our weekly round-up of the latest bariatric and obesity-related papers published in the medical literature. As ever, we have...


ARMMS-T2D study alliance continues to show benefits of MBS over medical interventions for those with T2DM
The 12-year Alliance of Randomized Trials of Medicine vs Metabolic Surgery in Type 2 Diabetes (ARMMS-T2D) clinical trial continues to...


Allurion reveals data showing lean mass gains in patients experiencing 14% weight loss
Allurion Technologies has announced the publication of a study demonstrating an average lean mass gain of 5.6% in patients with an...


Innovent’s GLORY-1 trial assessing mazdutide meets its primary endpoints
Innovent Biologics has announced the key results of the first Phase 3 clinical trial of mazdutide in Chinese adults with overweight or...


Semaglutide leads to greater weight loss in women than men with heart failure
Semaglutide significantly improves symptoms in men and women with a common type of heart failure that has had few therapeutic options....
Browse by tag






bottom of page